Induced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review.
Duy Cao Phuong LeHoa The BuiYen Thi Hai VuQuan Duy VoPublished in: Regenerative medicine (2024)
Background: Heart failure (HF) causes over 266,400 deaths annually. Despite treatment advancements, HF mortality remains high. Induced pluripotent stem cells (iPSCs) offer promising new options. This review assesses iPSC-based treatments for HF. Method: the review included studies from PubMed, ScienceDirect and Web of Science. Results: Analysis of 25 studies with 553 animals showed a baseline ejection fraction (EF) of 39.2 ± 8.9%. iPSC treatment significantly improved EF (MD = 8.6, p < 0.001) and fractional shortening (MD = 6.38, p < 0.001), and reduced ventricular remodeling without increasing arrhythmia risk. Conclusion: iPSC-based therapy improves heart function and reduces ventricular volumes in HF animal models, aligning with promising early clinical trial outcomes.
Keyphrases
- heart failure
- induced pluripotent stem cells
- systematic review
- clinical trial
- stem cells
- ejection fraction
- acute heart failure
- left ventricular
- randomized controlled trial
- risk factors
- cardiovascular disease
- public health
- study protocol
- adipose tissue
- cardiac resynchronization therapy
- bone marrow
- skeletal muscle
- catheter ablation
- weight loss
- aortic valve
- double blind
- glycemic control